Etanercept biosimilar (Bio Sidus S.A)

依那西普生物类似药 (Bio Sidus S.A)

Report date: 2025/07/31 13:30:09

Base Information

Drug NameEtanercept biosimilar (Bio Sidus S.A)

Drug Alias Name依那西普生物仿制药 (Bio Sidus S.A)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors

TargetsTumor necrosis factor αTumor necrosis factor β

Therapy Area/IndicationsAutoimmune DiseasesArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesBiosidus

China Registration ClassN/A

Active CompaniesBiosidus

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesArthritis, Rheumatoid

Inactive IndicationsN/A

ATC CodeL04AB01